⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 19, 2024Frontiers in OncologyOpen Access

The clinical outcome of pembrolizumab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a single center, real world study in China

Zongyu Fan Rong‐Rong Hui Houyu Ju Yunteng Wu Xuhui Ma Hao Song Yang Liu Mengyu Rui Xinrong Geng Minqi Zhao Yingye Xin Dongliang Wei Guoxin Ren

View Full Paper

Ask AI

Bookmark

Share

Abstract

The KEYNOTE-048 and KEYNOTE-040 study have demonstrated the efficacy of pembrolizumab in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC), we conducted this real-world study to investigate the efficacy of pembrolizumab in patients with R/M HNSCC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Fan et al. (2024) studied this question.

synapsesocial.com/papers/68e78968b6db6435876fc09c https://doi.org/10.3389/fonc.2024.1360657

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis2024 · 10 citations
2Clinical Outcomes of Pembrolizumab in Head and Neck Squamous Cell Carcinoma Subsites Excluded from the KEYNOTE-048 TrialCohort Study · 2026
3Comparative analysis of pembrolizumab and cetuximab-based therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma: Real-world data.2024 · 2 citations
4A multicenter, retrospective study analysis: Evaluating the efficacy and safety of pembrolizumab in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma.2024 · 2 citations
5Real-World Evidence on the Effectiveness of Pembrolizumab in Patients With Recurrent/Metastatic/Unresectable Head and Neck Squamous Cell Cancer: A Systematic Review and Meta-AnalysisMeta-Analysis · 2025 · 2 citations

More related papers

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort2016
The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (<scp>HNSCC</scp>) in the <scp>UK</scp>2024
Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial2024

More from Frontiers in Oncology

Case Report: Primary splenic angiosarcoma: a case report and literature reviewMon,
Case Report: A case of early rapid recurrence of a primary intracranial alveolar soft part sarcoma with high proliferative activity and complex molecular variationsThu,